Article | Published:

Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery

Nature Biotechnology volume 25, pages 12981306 (2007) | Download Citation

Subjects

Abstract

Achieving the full potential of zinc-finger nucleases (ZFNs) for genome engineering in human cells requires their efficient delivery to the relevant cell types. Here we exploited the infectivity of integrase-defective lentiviral vectors (IDLV) to express ZFNs and provide the template DNA for gene correction in different cell types. IDLV-mediated delivery supported high rates (13–39%) of editing at the IL-2 receptor common γ-chain gene (IL2RG) across different cell types. IDLVs also mediated site-specific gene addition by a process that required ZFN cleavage and homologous template DNA, thus establishing a platform that can target the insertion of transgenes into a predetermined genomic site. Using IDLV delivery and ZFNs targeting distinct loci, we observed high levels of gene addition (up to 50%) in a panel of human cell lines, as well as human embryonic stem cells (5%), allowing rapid, selection-free isolation of clonogenic cells with the desired genetic modification.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Generating mice with targeted mutations. Nat. Med. 7, 1086–1090 (2001).

  2. 2.

    , , , & Gene conversion: mechanisms, evolution and human disease. Nat. Rev. Genet. 8, 762–775 (2007).

  3. 3.

    , , , & Gene correction in hematopoietic progenitor cells by homologous recombination. Proc. Natl. Acad. Sci. USA 97, 13807–13811 (2000).

  4. 4.

    & Homologous recombination in human embryonic stem cells. Nat. Biotechnol. 21, 319–321 (2003).

  5. 5.

    The cultural mouse. Nat. Med. 7, 1081–1083 (2001).

  6. 6.

    Forty years with homologous recombination. Nat. Med. 7, 1083–1086 (2001).

  7. 7.

    & Gene targeting with viral vectors. Mol. Ther. 12, 9–17 (2005).

  8. 8.

    et al. Chance or necessity? Insertional mutagenesis in gene therapy and its consequences. Mol. Ther. 9, 5–13 (2004).

  9. 9.

    et al. Genome-wide analysis of retroviral DNA integration. Nat. Rev. Microbiol. 3, 848–858 (2005).

  10. 10.

    et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol. 24, 687–696 (2006).

  11. 11.

    , & Genotoxicity of retroviral integration in hematopoietic cells. Mol. Ther. 13, 1031–1049 (2006).

  12. 12.

    et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296, 2410–2413 (2002).

  13. 13.

    et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364, 2181–2187 (2004).

  14. 14.

    , , & Gene therapy for severe combined immunodeficiency. Annu. Rev. Med. 56, 585–602 (2005).

  15. 15.

    et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1–EVI1, PRDM16 or SETBP1. Nat. Med. 12, 401–409 (2006).

  16. 16.

    et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415–419 (2003).

  17. 17.

    , , , & Gene therapy: therapeutic gene causing lymphoma. Nature 440, 1123 (2006).

  18. 18.

    et al. Gene therapy: X-SCID transgene leukaemogenicity. Nature 443, E5; discussion E6–7 (2006).

  19. 19.

    et al. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 306, 1796–1799 (2004).

  20. 20.

    et al. Trans-splicing repair of CD40 ligand deficiency results in naturally regulated correction of a mouse model of hyper-IgM X-linked immunodeficiency. Nat. Med. 10, 835–841 (2004).

  21. 21.

    et al. Gene targeting in stem cells from individuals with osteogenesis imperfecta. Science 303, 1198–1201 (2004).

  22. 22.

    et al. Gene targeting in vivo by adeno-associated virus vectors. Nat. Biotechnol. 24, 1022–1026 (2006).

  23. 23.

    The phiC31 integrase system for gene therapy. Curr. Gene Ther. 6, 633–645 (2006).

  24. 24.

    & Gene targeting using zinc finger nucleases. Nat. Biotechnol. 23, 967–973 (2005).

  25. 25.

    & Chimeric nucleases stimulate gene targeting in human cells. Science 300, 763 (2003).

  26. 26.

    et al. Stimulation of homologous recombination through targeted cleavage by chimeric nucleases. Mol. Cell. Biol. 21, 289–297 (2001).

  27. 27.

    , & Repetitive zinc-binding domains in the protein transcription factor IIIA from Xenopus oocytes. EMBO J. 4, 1609–1614 (1985).

  28. 28.

    , & Design and selection of novel Cys2His2 zinc finger proteins. Annu. Rev. Biochem. 70, 313–340 (2001).

  29. 29.

    et al. Zinc-finger protein-targeted gene regulation: genomewide single-gene specificity. Proc. Natl. Acad. Sci. USA 100, 11997–12002 (2003).

  30. 30.

    , & Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc. Natl. Acad. Sci. USA 93, 1156–1160 (1996).

  31. 31.

    , , & FokI dimerization is required for DNA cleavage. Proc. Natl. Acad. Sci. USA 95, 10570–10575 (1998).

  32. 32.

    & The role of double-strand break repair - insights from human genetics. Nat. Rev. Genet. 7, 45–54 (2006).

  33. 33.

    et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 435, 646–651 (2005).

  34. 34.

    et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 263–267 (1996).

  35. 35.

    , , , & Novel integrase-defective lentiviral episomal vectors for gene transfer. Hum. Gene Ther. 15, 361–372 (2004).

  36. 36.

    et al. Transient gene expression by nonintegrating lentiviral vectors. Mol. Ther. 13, 1121–1132 (2006).

  37. 37.

    et al. Effective gene therapy with nonintegrating lentiviral vectors. Nat. Med. 12, 348–353 (2006).

  38. 38.

    et al. Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo. Proc. Natl. Acad. Sci. USA 103, 17684–17689 (2006).

  39. 39.

    , , & Human immunodeficiency virus type 1 integrase mutants retain in vitro integrase activity yet fail to integrate viral DNA efficiently during infection. J. Virol. 70, 721–728 (1996).

  40. 40.

    , , , & Gene conversion tracts from double-strand break repair in mammalian cells. Mol. Cell. Biol. 18, 93–101 (1998).

  41. 41.

    Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu. Rev. Immunol. 22, 625–655 (2004).

  42. 42.

    , , & CCR5: no longer a “good for nothing” gene–chemokine control of West Nile virus infection. Trends Immunol. 27, 308–312 (2006).

  43. 43.

    et al. Derivation of embryonic stem-cell lines from human blastocysts. N. Engl. J. Med. 350, 1353–1356 (2004).

  44. 44.

    , , , & Human immunodeficiency virus type 1 incorporated with fusion proteins consisting of integrase and the designed polydactyl zinc finger protein E2C can bias integration of viral DNA into a predetermined chromosomal region in human cells. J. Virol. 80, 1939–1948 (2006).

  45. 45.

    & Tethering human immunodeficiency virus type 1 preintegration complexes to target DNA promotes integration at nearby sites. J. Virol. 71, 458–464 (1997).

  46. 46.

    , , , & Modulating target site selection during human immunodeficiency virus DNA integration in vitro with an engineered tethering factor. Hum. Gene Ther. 17, 960–967 (2006).

  47. 47.

    et al. Complementation of integrase function in HIV-1 virions. EMBO J. 16, 5123–5138 (1997).

  48. 48.

    & Mechanism of homologous recombination: mediators and helicases take on regulatory functions. Nat. Rev. Mol. Cell Biol. 7, 739–750 (2006).

  49. 49.

    et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447, 799–816 (2007).

  50. 50.

    et al. An improved zinc-finger nuclease architecture for highly specific genome editing. Nat. Biotechnol. 25, 778–785 (2007).

  51. 51.

    , , , & Proteasome activity restricts lentiviral gene transfer into hematopoietic stem cells and is down-regulated by cytokines that enhance transduction. Blood 107, 4257–4265 (2006).

  52. 52.

    & Generation of HIV-1 derived lentiviral vectors. Methods Enzymol. 346, 454–465 (2002).

  53. 53.

    , , , & Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat. Med. 12, 585–591 (2006).

Download references

Acknowledgements

We are grateful to Lucia Sergi Sergi and Anna Zingale for technical help, Giovanna Lazzari for advice with HUES cultures, Rosa Bacchetta and Alessandro Aiuti for providing lymphoblastoid cells, Brian Brown and Bernhard Gentner for helpful discussion. We also thank Russell DeKelver, Jianbin Wang, Aleida Perez and Anna Lam for donor DNA construct generation, Jeffrey Miller, Victor Bartsevich, Dmitry Guschin, Igor Rupniewski, Yanhong Kong, Edward Rebar, Lei Zhang, Adam Waite, Deng Xia, Sarah Hinkley and members of the Sangamo production group for the design and generation of the ZFNs used in this study, and Sean Brennan for reading the manuscript. Research was supported by grants from Telethon (TIGET), National Institutes of Health (2 P01 HL053750-11 CFDA No. 93.839), EU (CONSERT, LSHB-CT-2004-005242) and Sangamo BioSciences to L.N., and European Science Foundation (EUROCORES Programme, EuroSTELLS) to C.G. HUES were kindly provided by D. Melton from Harvard Stem Cell Institute, under specific Materials Transfer Agreement to C.G.

Author information

Author notes

    • Christian M Beausejour

    Present address: Département de Pharmacologie, Centre de Recherche, CHU Ste-Justine 3175, Côte Ste-Catherine, Montréal, Quebec H3T 1C5, Canada.

    • Philip D Gregory
    • , Michael C Holmes
    •  & Luigi Naldini

    These authors contributed equally to this work.

Affiliations

  1. San Raffaele Telethon Institute for Gene Therapy, via Olgettina, 58, 20132 Milan, Italy.

    • Angelo Lombardo
    • , Pietro Genovese
    •  & Luigi Naldini
  2. “Vita Salute San Raffaele” University, via Olgettina, 58, 20132 Milan, Italy.

    • Angelo Lombardo
    • , Pietro Genovese
    •  & Luigi Naldini
  3. Sangamo BioSciences, Inc., Pt. Richmond Tech Center, 501 Canal Blvd., Suite A100 Richmond, California 94804, USA.

    • Christian M Beausejour
    • , Ya-Li Lee
    • , Kenneth A Kim
    • , Dale Ando
    • , Fyodor D Urnov
    • , Philip D Gregory
    •  & Michael C Holmes
  4. Reproductive Technologies Laboratory, CIZ, Istituto Sperimentale Italiano Lazzaro Spallanzani, via Porcellasco 7/F, 26100 Cremona, Italy.

    • Silvia Colleoni
    •  & Cesare Galli
  5. Dipartimento Clinico Veterinario, University of Bologna, Via Tolara di Sopra 50, 40064 Ozzano Emilia, Italy.

    • Cesare Galli

Authors

  1. Search for Angelo Lombardo in:

  2. Search for Pietro Genovese in:

  3. Search for Christian M Beausejour in:

  4. Search for Silvia Colleoni in:

  5. Search for Ya-Li Lee in:

  6. Search for Kenneth A Kim in:

  7. Search for Dale Ando in:

  8. Search for Fyodor D Urnov in:

  9. Search for Cesare Galli in:

  10. Search for Philip D Gregory in:

  11. Search for Michael C Holmes in:

  12. Search for Luigi Naldini in:

Contributions

A.L. designed, performed experiments and wrote the paper; P.G., C.M.B., Y.-L.L. and K.A.K. performed experiments; S.C. performed ES cell cultures; D.A. and F.D.U. designed experiments; C.G. coordinated ES cell work; P.D.G. and M.C.H. designed experiments and wrote the paper; and L.N. coordinated the project, designed experiments and wrote the paper.

Competing interests

C.M.B., Y.-L.L., K.A.K., D.A., F.U., P.D.G. and M.C.H. are current or former employees of Sangamo BioSciences, Inc. Work in L.N.'s laboratory was supported in part by a research collaboration agreement with Sangamo BioSciences.

Corresponding author

Correspondence to Luigi Naldini.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–9; Supplementary Methods

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nbt1353

Further reading